Skip to content
INVESTORS & MEDIA
Markus Renschler, MD
President & Chief Executive Officer
Barbara Wan, PhD
VP, Research & Development Project Leadership
Jean-Marc Lapierre, PhD
VP, Clinical Operations
Tom O'Shea, PhD
SVP, Clinical Pharmacology & Preclinical Development
Chief Business Officer
Paul Secrist, Ph.D.
Chief Scientific Officer
Judson Englert, M.D., Ph.D.
VP, Clinical Research & Development
“It is with patients in the forefront of our minds that we work diligently to develop novel gain of function synthetic lethal therapies”
Melinda Anne Lynch Day, PhD – Principal Scientist, Cyteir Therapeutics, Inc.
Go to Top